Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum-Reference-Cited by-同舟云学术

Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum

Published:2019-10-29 Issue:5 Volume:70 Page:1841-1855
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Cheung Amanda¹,Neuschwander‐Tetri Brent A.²^ORCID,Kleiner David E.³,Schabel Elmer⁴,Rinella Mary⁵,Harrison Stephen⁶,Ratziu Vlad⁷,Sanyal Arun J.⁸,Loomba Rohit⁹,Jeannin Megnien Sophie¹⁰,Torstenson Richard¹¹,Miller Veronica¹²,

Affiliation:

1. Stanford Hospital and Clinics, Division of Gastroenterology and Hepatology Stanford University Stanford CA

2. Division of Gastroenterology and Hepatology Saint Louis University St. Louis MO

3. National Cancer Institute Bethesda MD

4. Gastroenterology & Hepatology Unit Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany/European Medicines Agency London United Kingdom

5. Feinberg School of Medicine Northwestern University Chicago IL

6. Pinnacle Clinical Research San Antonio TX

7. Department of Hepatology and Gastroenterology Hôpital Pitié Salpêtrière et Université Pierre et Marie Curie Paris France

8. Division of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University Richmond VA

9. Division of Gastroenterology University of California San Diego School of Medicine San Diego CA

10. Summit Clinical Research Cambridge MA

11. Novo Nordisk A/S Copenhagen Denmark

12. Forum for Collaborative Research University of California School of Public Health Berkeley CA

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.30672

Reference50 articles.

1. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop

2. Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum

3. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science

4. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

5. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A roadmap for clinical trials in MASH-related compensated cirrhosis;Nature Reviews Gastroenterology & Hepatology;2024-07-17

2. Endoscopic duodenal mucosa ablation techniques for diabetes and nonalcoholic fatty liver disease: A systematic review;Med;2024-07

3. Development of Therapy for Liver Fibrosis: Molecular/cellular basis and overcoming challenges;Kanzo;2024-07-01

4. AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis;Hepatology;2024-03-15

5. Endpoints in NASH Clinical Trials: Are We Blind in One Eye?;Metabolites;2024-01-08